<DOC>
	<DOCNO>NCT01850797</DOCNO>
	<brief_summary>The registry acute stroke new oral anticoagulant ( RASUNOA ) German multicenter , prospective , observational registry perform 50 study center cover 50.000 acute ischemic stroke 6000 acute intracranial hemorrhage per year . Study enrollment consecutive . The RASUNOA registry study center University Medical Center Principal Investigator ( Heidelberg , Germany ) . The registry focus treatment decision concepts patient treatment new oral anticoagulant suffer acute ischemic hemorrhagic stroke .</brief_summary>
	<brief_title>Registry Acute Stroke Under New Oral Anticoagulants -Pilot ( RASUNOA-Pilot )</brief_title>
	<detailed_description>The main purpose study collect information large , prospectively enrol multicentre stroke database regard optimal management ischemic hemorrhagic stroke anticoagulation nOAC . Specifically , aim obtain critical information regard epidemiology , natural history , laboratory neuroradiological aspect , clinical consequence , effect treatment ( i.e . thrombolysis/interventional recanalisation ischemic stroke hemostatic therapy ICH , respectively ) stroke nOAC . The Registry limit specific new OAC intend examine stroke use approve nOAC . The study design perform comparison among different nOAC .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>age &gt; = 18 year informed consent acute stroke intracranial bleeding therapy new oral anticoagulant ( Dabigatran速 , Rivaroxaban速 , Apixaban速 , Edoxaban速 ) miss inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>oral anticoagulant</keyword>
	<keyword>ischemic stroke</keyword>
	<keyword>blood thinner</keyword>
	<keyword>intracranial hemorrhage</keyword>
</DOC>